PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's environmental, social, and governance practices.
46.92
ESG score below 80% of Biotechnology median of 60.77. Michael Burry would check for potential stranded assets and regulatory compliance issues.
27.98
Environmental score below 80% of Biotechnology median of 57.16. Michael Burry would check for potential carbon tax exposure and regulatory compliance costs.
55.48
Social score 80-90% of Biotechnology median of 64.27. Martin Whitman would look for hidden social liabilities and reputational risks.
57.30
Governance score 90-95% of Biotechnology median of 62.45. John Neff would demand higher returns to compensate for below-average governance oversight.